Pleiotropic Effects of Proton Pump Inhibitors  
Guest Editor: Yuji Naito

Prevention of NSAID-Induced Small Intestinal Mucosal Injury: Prophylactic Potential of Lansoprazole

Kazuhide Higuchi1,* Yukiko Yoda1 Kikuko Amagase2 Shinichi Kato5 Satoshi Tokioka1, Mitsuyuki Murano1, Koji Takeuchi2, and Eiji Umegaki1

12nd Department of Internal Medicine, Osaka Medical College, Daigakumachi, Takatsuki, Osaka 569-8686, Japan  
2Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University,  
Misasagi, Yamashina, Kyoto 607-8414, Japan

Received 1 June, 2009; Accepted 9 June, 2009

Summary Non-steroidal anti-inflammatory drugs (NSAIDs), which are used for the treatment of several inflammatory disorders including rheumatoid arthritis, are well known to cause gastroduodenal mucosal lesions as an adverse effect. Recently, the serious problem of NSAID-induced small intestinal damage has become a topic of great interest to gastroenterologists, since capsule endoscopy and double-balloon enteroscopy are available for the detection of small intestinal lesions. Such lesions have been of great concern in clinical settings, and their treatment and prevention must be devised as soon as possible. Proton pump inhibitors (PPI), such as lansoprazole and omeprazole, show a potent anti-secretory effect. PPIs also have a gastroprotective effect, independent of their anti-secretory actions, which is probably mediated by inhibition of neutrophil functions as well as antioxidant actions. Administration of lansoprazole reduced the severity of the intestinal lesions in a dose-dependent manner, but omeprazole had no effect. The amount of heme oxygenase-1 (HO-1) protein in the intestinal mucosa was significantly increased by lansoprazole, but not by omeprazole. These results suggest that lansoprazole, but not omeprazole, ameliorates indomethacin-induced small intestinal ulceration through upregulation of HO-1/carbon monoxide. Therefore, lansoprazole may be useful for preventing the adverse effects of NSAIDs not only in the stomach but also in the small intestine.

Key Words: NSAID, small intestinal injury, lansoprazole, PPI

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) including indomethacin inhibit prostaglandin (PG) production at inflamed sites by the inhibition of cyclooxygenase (COX). NSAIDs are thought to demonstrate their anti-inflammatory, antipyretic, analgesic, and anti-platelet aggregation effects through this process. NSAIDs have been used widely in internal medicine and orthopedic surgery. They have been used to treat febrile diseases, inflammatory diseases, arthritis, lower back pain, and collagen diseases and to prevent and treat cerebrovascular diseases and ischemic heart diseases. PG is an important mediator in the inflammatory response. It also plays an important role in maintaining the homeostasis of many tissues and organs.
K. Higuchi et al.

**Mechanisms of NSAID-associated Small Bowel Injury**

First, elucidation of mechanism is necessary to devise measures for small-bowel injury due to NSAIDs. Much about this mechanism is unknown, but recently more information has become evident. A decrease in endogenous PG has been considered important in the development of NSAID-induced small-bowel injury [6]. PG is involved in regulation of gastrointestinal blood flow and various mucosal functions such as increasing mucous secretion. Thus, the decrease in PG production is considered to be the main cause of small bowel injuries due to NSAIDs. In a rat study, exogenous PG administration was reported to markedly inhibit small bowel injuries induced by indomethacin, an NSAID. Besides the reduction of intestinal mucus, NSAIDs cause microcirculatory disturbances accompanying abnormally increased intestinal motility. Inflammatory cytokines are induced and neutrophil infiltration occurs. Then intestinal mucosal injuries can occur [7]. The involvement of NO derived from iNOS is also considered important in the development of such injuries [8–11].

Bjarnason et al. [12] stated that injury to small bowel mucosa involves the disruption of intercellular junctions, resulting in increased mucosal permeability. The disruption of intercellular junctions occurs because NSAIDs inhibit the production of mitochondrial ATP in intestinal epithelial cells. With increased mucosal permeability, mucosal injuries can be caused by the penetration of bile acid, proteolytic enzymes, intestinal bacteria, or toxins. Since indomethacin-induced small-bowel injuries do not develop in rats with germ-free intestines [13], the involvement of intestinal bacteria has been reported to be very important in such injuries. Watanabe et al. studied small bowel injuries...
induced by indomethacin in rats. They reported that a pathway mediated by lipopolysaccharide (LPS)/toll-like receptor 4 (TLR4) plays an important role in the development of such injuries [14]. That is, NSAID-induced small-intestinal mucosal injuries begin with a PG decrease just as in NSAID-induced gastric mucosal injuries. Then mucosal protection declines and microcirculatory disturbances occur. Unlike gastric mucosal injuries, bacteria in the small intestine are thought to play an important role instead of gastric acid (Fig. 1). As mentioned before, NSAIDs inhibit mucosal PG synthesis by inhibiting COX activity. There are two types of COX: COX-1 and 2. In particular, COX-1 derived PG has been considered important in maintaining homeostasis of intestinal mucosa. In recent years, a study using an animal model has shown that small-intestinal mucosal injuries occurred only after both COX-1 and 2 were inhibited [15].

**Prophylactic Potential of Lansoprazole to NSAID-induced Small Bowel Injury**

PPI has a strong inhibitory effect on gastric acid secretion. PPI has been used widely in a clinical setting for *Helicobacter pylori* eradication and for the treatment of gastric ulcers, duodenal ulcers, reflux esophagitis and NSAID-induced gastric lesions [16–18]. PPI is also known to have protective effects on gastrointestinal mucosa without the inhibition of acid secretion [19–21]. These protective effects have been reported to occur via anti-inflammatory effects such as the inhibition of IL-8 production and neutrophil infiltration and via cell injury repair through MAPK [22–24]. A study was conducted using a rat model for small-intestinal mucosal injuries due to ischemia and reperfusion. Such injuries are said to involve neutrophils and reactive oxygen species. Lansoprazole inhibited small-intestinal mucosal injuries due to ischemia and perfusion via inhibition of neutrophils, lipid peroxidation, and inflammatory cytokine induction [25]. In addition, PPIs also reduced NSAID-induced small-intestinal mucosal injuries [26, 27].

We examined the effectiveness of lansoprazole compared with omeprazole. Male SD rats (200–300 g) were orally administered 10 mg/kg of indomethacin (IM) and small bowel injuries were created. Lansoprazole (30–100 mg/kg) inhibited small bowel injuries in a dose-dependent manner. Its effectiveness was significant at doses of 60 mg/kg or more, and the inhibition of 80% or more was observed at a dose of 100 mg/kg (Fig. 2) [28]. In contrast, omeprazole did not inhibit such injury at any of the tested doses (30–100 mg/kg). Pretreatment with lansoprazole inhibited the MPO activity and iNOS mRNA expression which were increased by indomethacin. The different effectiveness of lansoprazole compared with omeprazole cannot be fully explained by previously reported mechanisms [29–32].

![Graph showing effects of lansoprazole on indomethacin-induced intestinal lesions](image)

**Fig. 2.** Effects of lansoprazole on indomethacin-induced intestinal lesions in rats. Animals were given indomethacin (10 mg/kg, p.o.) and sacrificed 24 h later. Lansoprazole (30, 60, and 100 mg/kg) were given p.o. 30 min before the administration of indomethacin. Data are presented as the mean ± SE from 6 rats. *Statistically significant difference from control (vehicle alone) at p<0.05. Reprinted with permission [28].

**An Anti-inflammatory Effect of Lansoprazole via Upregulation of HO-1/CO**

The development of NSAID-induced ulcers cannot be explained by PG reduction alone. It has been recently reported that NSAID-induced cell death of gastric mucosa is necessary in the mechanism of NSAID-associated gastric mucosal injury [33, 34]. NSAIDs induce heme oxygenase-1 (HO-1) and this induction inhibits NSAID-dependent cell death. HO-1 is also called heat shock protein 32 (HSP 32) and is the rate limiting enzyme of heme metabolism. It degrades free heme which has high cytotoxicity. This degradation produces highly cytoprotective carbon monoxide (CO) and biliverdin, resulting in a cytoprotective effect [35–37] (Fig. 3). In recent years, CO has been reported to demonstrate a strong anti-inflammatory effect. CO has shown this effect by p38 MAP kinase activation, inhibiting the production of inflammatory cytokines, such as TNF-α and IL-1β, and inducing the production of anti-inflammatory cytokine, IL-10 [38–40].

Mizushima et al. [41]. reported the following three points. NSAID-induced cell death of gastric mucosa is essential in the development of NSAID-induced gastric ulcers. NSAIDs induce HO-1 in vitro and in vivo via Nrf2 activation. This induction inhibits NSAID-dependent cell death of gastric mucosa, resulting in the inhibition of the development of NSAID-induced ulcers. HO-1 expression is induced mainly...
in macrophage cell lines and vascular endothelial cells under various stresses such as exposure to heavy metals and active oxygen species. When there is an increase in heme degradation by HO-1, cytoprotection occurs by the biochemical actions of various resulting degradation products \[42, 43\]. In addition, lansoprazole has been reported to induce HO-1 \[44\], and thus, HO-1 is thought to be involved in the inhibition of NSAID-associated small bowel injuries. We intravenously administered an HO-1 inhibitor SnPP (30 mg/kg) in rats \[45\]. It was administered 10 min before indomethacin administration. Pretreatment with SnPP aggravated small bowel injuries induced by indomethacin. On the contrary, pretreatment with both lansoprazole (100 mg/kg) and SnPP clearly aggravated mucosal injuries. HO-1 expression was examined using an ELISA kit (Stressgen, Rat HO-1 ELISA Kit) and immunoreaction. HO-1 is usually not expressed in normal rats. It was expressed in the mucosal epithelium 6 h after indomethacin (10 mg/kg) and lansoprazole (100 mg/kg) administrations. These results suggested that HO-1 is involved in the mechanism for inhibiting indomethacin-induced small bowel injuries using lansoprazole. CORM-2 (10 mg/kg) was administered intraperitoneally 30 min before and 6 h after indomethacin administration. Indomethacin-induced small bowel injuries were markedly inhibited. iNOS mRNA expression was also inhibited 6 h after indomethacin administration. In a recent study, CO released by CORM-2 was reported to inhibit NO and TNF-α production in mice \[46, 47\]. There has been a report indicating that CO has an anti-inflammatory effect in DLD-1, a human colorectal cancer cell line \[48\]. Another report indicated that CO has an anti-inflammatory effect by inhibiting NFκB activity \[49, 50\]. Still another report showed that indomethacin activates NFκB in the small intestine, and the immunosuppressant tacrolimus inhibits NFκB activity \[51\]. Thus, lansoprazole inhibits NFκB activity via upregulation of HO-1/CO, suggesting the possible involvement of iNOS inhibition.

**Conclusion**

We have described the mechanism of and potential measures for NSAID-induced small-bowel injuries. The whole gastrointestinal tract must be managed in this era of increasing NSAID use. In considering this point, we can say that lansoprazole is a useful drug that can potentially protect the stomach and small intestine. We hope to examine these issues in future clinical studies.

**References**

[1] Higuchi, K., Umegaki, E., Watanabe, T., Yoda, Y., Morita, E., Murano, M., Tokioka, S., and Arakawa, T.: Present status and strategy of NSAIDs-induced small bowel injury. *J. Gastroenterol.*, Jul 1 2009 [Epub ahead of print].

[2] Graham, D.Y., Opekun, A.R., Willingham, F.F., and Qureshi,
Prevention of NSAID-induced small intestinal injury

W.A.: Visible small-intestinal mucosal injury in chronic NSAID users. Clin. Gastroenterol. Hepatol., 3, 55–59, 2005.

[3] Kameda, N., Higuchi, K., Shiba, M., Machida, H., Okazaki, H., Yamagami, H., Tanigawa, T., Watanabe, K., Watanabe, T., Tominaga, K., Fujiwara, Y., Oshitan, N., and Arakawa, T.: A prospective, single-blind trial comparing wireless capsule endoscopy and double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. J. Gastroenterol., 43, 434–440, 2008.

[4] Watanabe, T., Sugimori, S., Kameda, N., Machida, H., Okazaki, H., Tanigawa, T., Watanabe, K., Tominaga, K., Fujiwara, Y., Oshitan, N., Higuchi, K., and Arakawa, T.: Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin. Gastroenterol. Hepatol., 6, 1279–1282, 2008.

[5] Sugimori, S., Watanabe, T., Tabuchi, M., Kameda, N., Machida, H., Okazaki, H., Tanigawa, T., Yamagami, H., Shiba, M., Watanabe, K., Tominaga, K., Fujiwara, Y., Oshitan, N., Koike, T., Higuchi, K., and Arakawa, T.: Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion, 78, 208–213, 2008.

[6] Konaka, A., Tanaka, A., Kato, S., Nishijima, M., and Takeuchi, K.: Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced intestinal lesions in rats. J. Pharmacol. Physiol., 50, 25–38, 1999.

[7] Takeuchi, K., Miyazawa, T., Tanaka, A., Kato, S., and Kunikata, T.: Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion, 66, 30–41, 2002.

[8] Whittle, B.J.: Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology, 80, 94–98, 1981.

[9] Boughton-Smith, N.K., Evans, S.M., Laszlo, F., Whittle, B.J., and Moncada, S.: The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br. J. Pharmacol., 110, 1189–1195, 1993.

[10] Whittle, B.J.R., Laszlo, F., Evans, S.M., and Moncada, S.: Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br. J. Pharmacol., 116, 2286–2290, 1995.

[11] Tanaka, A., Kunihata, T., Mizoguchi, H., Kato, S., and Takeuchi, K.: Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J. Physiol. Pharmacol., 50, 405–417, 1999.

[12] Bjarnason, I., Hayllar, J., MacPherson, A.J., and Russell, A.S.: Side effects of nonsteroidal anti-inflammatory drugs on the small intestine in humans. Gastroenterology, 104, 1832–1847, 1993.

[13] Robert, A. and Asano, T.: Resistance of germ-free rats to indomethacin-induced intestinal inflammation. Prostaglandins, 14, 333–341, 1977.

[14] Watanabe, T., Higuchi, K., Kobata, A., Nishio, H., Tanigawa, T., Shiba, M., Tominaga, K., Fujiwara, Y., Oshitan, N., Asahara, T., Nomoto, K., Takeuchi, K., and Arakawa, T.: Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut, 57, 181–187, 2008.

[15] Sigthorsson, G., Simpson, R.J., Walley, M., Anthony, A., Foster, R., Hotz-BeWoedtitz, C., Palizban, A., Pombo, J., Watts, J., Morham, S.G., and Bjarnason, I.: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology, 122, 1913–1923, 2002.

[16] Langtry, H.D. and Wilde, M.J.: Omeprazole. A review of its use in Helicobacter pylori infection, gastro-esophageal reflux disease and peptic ulcers impaired by non-steroidal anti-inflammatory drugs. Drugs, 56, 447–486, 1998.

[17] Sachs, G., Shin, J.M., Briving, C., Wallmark, B., and Hersey, S.: The pharmacology of the gastric acid pump: the H+ K+ ATPase. Annu. Rev. Pharmacol. Toxicol., 35, 277–305, 1995.

[18] Hawkey, C.J., Karrasch, J.A., Szczepański, L., Walker, D.G., Barkun, A., Swannell, A.J., and Yeomans, N.D.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) study Group. N. Engl. J. Med., 338, 727–734, 1998.

[19] Fukuda, T., Arakawa, T., Shimizu, Y., Ohtani, K., Higuchi, K., and Kobayashi, K.: Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa. J. Clin. Gastroenterol., 20, 55–57, 1995.

[20] Natale, G., Lazzeri, G., Lubrano, V., Colucci, R., Vassalle, C., Fornai, M., Blandizzi, C., and Del Tacca, M.: Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. Toxicol. Appl. Pharmacol., 195, 62–72, 2004.

[21] Fornai, M., Natale, G., Colucci, R., Tuccori, M., Carazzina, G., Antonioli, L., Baldi, S., Lubrano, V., Abramo, A., Blandizzi, C., and Del Tacca, M.: Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch. Pharmacol., 372, 79–87, 2005.

[22] Wandall, J.H.: Effect of omeprazole on neutrophil chemotaxis, super oxide production, degradation and tranlocation of cytochrome b-245. Gut, 33, 617–621, 1992.

[23] Yoshida, N., Yoshikawa, T., Tanaka, Y., Fujita, N., Kassai, K., Naito, Y., and Kondo, M.: A new mechanism for anti-inflammatory actions of proton pump inhibitors— inhibitory effects on neutrophil-endothelial cell interactions. Aliment. Pharmacol. Ther., 14, S74–S81, 2000.

[24] Biswas, K., Bandyopadhyay, U., Chattopadhyay, I., Varadaraj, A., Ali, E., and Banerjee, R.K.: A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J. Biol. Chem., 278, 10993–11001, 2003.

[25] Ichikawa, H., Yoshihda, N., Takagi, T., Tomatsu, N., Katada, K., Iszakiof, Y., Uchiyama, K., Naito, Y., Okanoue, T., and Yoshikawa, T.: Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J. Gastroenterol., 10, 2814–2817, 2004.

[26] Kuroda, M., Yoshida, N., Ichikawa, H., Takagi, T., Okuda, T,
Naito, Y., Okanoue, T., and Yoshikawa, T.: Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. *Int. J. Mol. Med.*, 17, 89–93, 2006.

[27] Pozzoli, C., Menozzi, A., Grandi, D., Solenghi, E., Osiprandi, M.C., Zullian, C., Bertini, S., Casvetro, G.M., and Coruzzi, G.: Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. *Naunyn-Schmiedebergs Arch. Pharmacol.*, 374, 283–291, 2007.

[28] Yoda, Y., Takeuchi, K., Kato, S., Amagase, K., Umegaki, E., Tokioka, S., and Higuchi, K.: Search for prophylactic drugs against NSAID-Induced small Intestinal lesions in rats. *Gastroenterology*, 134, suppl. 1, A-528, 2008.

[29] Naito, Y.: Anti-inflammatory and anti-oxidative properties of proton pump inhibitors. *J. Clin. Biochem. Nutr.*, 41, 82–83, 2007.

[30] Isomoto, H., Nishi, Y., Kanazawa, Y., Shikuwa, S., Mizuta, Y., Inoue, K., and Kohno, S.: Immune and inflammatory responses in GERD and lansoprazole. *J. Clin. Biochem. Nutr.*, 41, 84–89, 2007.

[31] Mine, S. and Tanaka, Y.: Lansoprazole-induced improvement of esophageal submucosal injury. *J. Clin. Biochem. Nutr.*, 41, 92–96, 2007.

[32] Nakamura, M., Matsui, H., Serizawa, H., and Tsuchimoto, K.: Lansoprazole novel effector sites revealed by autoradiography: relation to *Helicobacter pylori*, colon, esophagus and others. *J. Clin. Biochem. Nutr.*, 41, 154–159, 2007.

[33] Tomisato, W., Tanaka, K., Katsu, T., Kakuta, H., Sasaki, K., Tsutsumi, S., Hoshino, T., Aburaya, M., Li, D., Tsuchiya, T., Suzuki, K., Yokomizo, K., and Mizushima, T.: Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. *Biochem. Pharmacol.*, 67, 575–585, 2004.

[34] Tomisato, W., Tanaka, K., Katsu, T., Kakuta, H., Sasaki, K., Tsutsumi, S., Hoshino, T., Aburaya, M., Li, D., Tsuchiya, T., Suzuki, K., Yokomizo, K., and Mizushima, T.: Membrane permeabilization by non-steroidal anti-inflammatory drugs. *Biochem. Biophys. Res. Commun.*, 323, 1032–1039, 2004.

[35] Tenhunen, R., Marver, H.S., and Schmid, R.: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc. Natl. Acad. Sci.*, 61, 748–755, 1968.

[36] Maines, M.D.: The heme oxygenase system: a regulator of monoxide provides protection against hyperoxic lung injury. *Am. J. Physiol.*, 276, L688–L694, 1999.

[37] Morisaki, H., Katayama, T., Kotake, Y., Ito, M., Handa, M., Ikeda, Y., Takeda, J., and Suematsu, M.: Carbon monoxide modulates endotoxin-induced microrascular leukocyte adhesion through platelet-dependent mechanisms. *Anesthesiology*, 97, 701–709, 2002.

[40] Sato, K., Balla, J., Otterbein, L., Smith, R.N., Brouard, S., Lin, Y., Csizmadia, E., Sevigny, J., Robson, S.C., Vercellotti, G., Choi, A.M., Bach, F.H., and Soares, M.P.: Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. *J. Immunol.*, 166, 4185–4194, 2001.

[41] Mizushima, T.: Induction of HO-1 by NSAIDs and its role in NSAID-induced gastric ulcers. *Nippon Yakurigaku Zasshi*, 130, 262–265, 2007.

[42] Morse, D. and Choi, A.M.: Heme oxygenase-1: the “emerging molecule” has arrived. *Am. J. Respir. Cell Mol. Biol.*, 27, 8–16, 2002.

[43] Otterbein, L.E., Soares, M.P., Yamashita, K., and Bach, F.H.: Heme oxygenase-1: unleashing the protective properties of heme. *Trends Immunol.*, 24, 49–55, 2003.

[44] Becker, J.C., Grosser, N., Waltke, C., Schulz, S., Erdmann, K., Domschke, W., Schröder, H., and Pohle, T.: Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. *Biochem. Biophys. Res. Commun.*, 345, 1014–1021, 2006.

[45] Yoda, Y., Higuchi, K., Takeuchi, K., Umegaki, E., Tokioka, S., Kato, S., and Amagase, K.: Proton pump inhibitor (PPI), lansoprazole prevents indomethacin-induced small intestinal ulceration in rats: Involvement of Heme Oxygenase (HO)-1. *Gastroenterology*, 136, suppl. 1, A-684, 2009.

[46] Sawle, P., Foresti, R., Mann, B.E., Johnson, T.R., Green, C.J., and Motterlini, R.: Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. *Br. J. Pharmacol.*, 145, 800–810, 2005.

[47] Bani-Hai, M.G, Greenstein, D., Mann, B.E., Green, C.J., and Motterlini, R.: Modulation of thrombin-induced neuro-inflammation in BV-2 microglia by carbon monoxide-releasing molecule 3. *J. Pharmacol. Exp. Ther.*, 318, 1315–1322, 2006.

[49] Minamoto, K., Harada, H., Lama, V.N., Fedarau, M.A., and Pinsky, D.J.: Reciprocal regulation airway rejection by the inducible gas-forming enzymes heme oxygenase and nitric oxide synthase. *J. Exp. Med.*, 202, 283–294, 2005.

[50] Megias, J., Busserolles, J., and Alcaraz, M.J.: The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. *Br. J. Pharmacol.*, 150, 977–986, 2007.

[51] Kato, S., Nishio, H., Ogura, M., and Takeuchi, K.: Tacrolimus (FK506), an immunosuppressive agent, prevents indomethacin-induced small intestinal ulceration in the rat: inhibition of inducible nitric oxide synthase expression. *J. Pharmacol. Sci.*, 103, 40–47, 2007.